Finding a Cure for the Cost of Durable Therapies

Panel Overview & Context

• Core Challenge: The panel addresses the friction between unprecedented advances in gene and cellular therapies (cures) and traditional commercial models that rely on large patient populations to amortize R&D costs.
• Scientific Landscape: Current science is delivering transformative treatments for previously incurable conditions, with approximately 1,000 ongoing studies focused on transformative therapies.
• Therapy Categories:
  • One-time cures: Gene therapies (e.g., Luxturna for blindness, hemophilia treatments) intended as "one-and-done."
  • Chronic durable therapies: Ongoing treatments (e.g., Alnylam's RNAi therapies for hereditary amyloidosis) requiring regular administration (monthly or bi-annually) to silence disease-causing genes.
  • Oncology innovations: Immuno-oncology (e.g., CAR-T) and combination therapies transforming cancer from a fatal prognosis to a manageable long-term condition.

Scientific Innovation & Commercial Strategy

• Alnylam Pharmaceuticals' Approach:
  • Focused on rare diseases like hereditary amyloidosis affecting ~50,000 patients globally, where the technology can delay progression and reverse disease features.
  • The company spent 16–20 years and raised ~$4 billion to commercialize its RNA interference technology.
  • Pricing for rare disease drugs currently ranges between $250,000 and $650,000 per year.
• High-Cost Examples:
  • Some curative genetic therapies for as few as 50 patients/year involve production constraints requiring patient airlifts, with costs described as "substantial" without specific pricing disclosed.
  • Future hemophilia gene therapies are projected to cost between $1.5 million and $3 million, though some industry observers believe costs may be lower.
• Value Proposition:
  • Stakeholders argue that high prices reflect true value where treatments reduce hospitalization, chronic illness burden, and mortality, even without immediate cost offsets.
  • Yvonne Greenstreet noted that Alnylam has publicly committed to capping price increases at CPI (Consumer Price Index) levels.

Payer Perspectives: Harvard Pilgrim Health Care

• Budget Impact & Premiums:
  • Drugs currently account for 25 cents of every health care dollar in Harvard Pilgrim's fully insured business; this share is projected to rise to 30–35% within 5–10 years.
  • The fastest-growing segment is the medical benefit (physician-administered infusions), growing at 15–20% annually, currently comprising only 5% of spend.
• Risk Management:
  • Unmanaged costs could drive premiums up, potentially leading to insured individuals dropping coverage due to affordability, creating adverse selection risks.
  • Payers currently lack sufficient "levers" (deductibles and cost-shares are often ineffective against million-dollar therapies), leaving premiums as the primary buffer.
• Innovative Contracting (Alnylam Pilot):
  • Harvard Pilgrim collaborated with Alnylam a year prior to approval to design a value-based agreement.
  • Mechanisms:
    • Prices reduce via rebates if patients are "sub-optimal responders."
    • If a patient requires a liver transplant (and was not on the list initially), the payer covers the transplant cost up to a specific cap.
  • Philosophy: Payers emphasize that "value" must be measured by outcomes relevant to the patient, not just clinical trial endpoints.

Patient Advocacy & Outcome Measurement

• Hemophilia Advocacy (Mark Skinner):
  • Patients emphasize that "value" must include quality of life, not just clinical metrics like "bleeding episodes," which can be managed sedentarily.
  • The hemophilia community engaged regulators (FDA, EMA), payers (six major US insurers), and developers (9 companies) to align on six core outcomes defining value prior to market entry.
• Alignment Challenges:
  • Traditional metrics (e.g., QALYs) often penalize rare diseases with small populations; stakeholders argue for flexible upper limits.
  • Patient-reported outcomes must be integrated into development phases (Phase I/II) rather than being an afterthought.
• Systemic Gaps:
  • Most of the 7,000 rare diseases lack organized patient support and managed care frameworks, risking neglect as the system focuses on high-volume conditions.
  • Current financial incentives for health plans favor controlling chronic diseases (diabetes, CVD) but do not reward the high upfront costs of managing rare, durable conditions.

Government Policy & Systemic Reform

• Office of Management and Budget (OMB) Priorities:
  • Drug pricing moderation is a daily priority; recent data shows a trajectory of moderated drug prices due to record generic approvals.
  • The government aims to create "headroom" for high-cost cures by eliminating system inefficiencies and reducing wastage.
• Policy Levers & Barriers:
  • "Best Price" regulations currently create disincentives for deep discounts, as favorable prices offered to specific payers (like Harvard Pilgrim) must be extended to all government payers, creating "free rider" problems.
  • Adverse Selection: Without federal mandates ensuring all plans cover specific therapies, self-insured employers could exclude them, causing financial collapse for plans that do cover them.
• Future Financing Models:
  • OMB is exploring innovative financial instruments, such as state-level bond issuances or securitization of therapy costs, to monetize value and spread risk.
  • A "holy grail" solution involves financial markets creating instruments where states and manufacturers agree on a monetizable financing vehicle sold on the open market.

Data, Value Metrics, & Future Outlook

• Data Infrastructure Gaps:
  • Current Real-World Evidence (RWE) and data collection infrastructures are woefully inadequate for rare diseases; existing models (RCTs) are often too slow or rigid.
  • Proposed Solution: Payers and manufacturers should agree on "all-or-none" payment structures where payment is contingent on real-world data confirming efficacy over time.
• Valuation Frameworks:
  • QALYs (Quality-Adjusted Life Years): The panel expressed skepticism about a single metric; while used in Europe, the US lacks a formal mechanism, and rigid QALY thresholds ($150,000 limit) unfairly penalize rare disease treatments.
  • Consensus: No single metric works for all diseases; value must be defined collaboratively by patients, payers, and manufacturers at the earliest stages of development.
• Forward-Looking Statements:
  • If pricing models and payment mechanisms are not modernized, the system faces a "crack up" where insurance becomes unaffordable.
  • The panel anticipates a shift from "paying for process" to "paying for value," requiring new models like pay-over-time, outcome-based rebates, and risk-sharing agreements.
  • The government is prepared to support state-level pilots and interagency coordination to flatten regulations and enable these new financing vehicles.